LRP1b Loss Predicts Sensitivity to Immunotherapy in Patients with NSCLC: An Analysis of the Phase III CheckMate-026 Randomized Trial

医学 内科学 肿瘤科 生物标志物 随机对照试验 化疗 临床试验 预测值 前瞻性队列研究 癌症 临床研究阶段 免疫检查点 免疫系统 免疫疗法 灵敏度(控制系统) 试验预测值 预测标记
作者
Andrew J. Armstrong,Hilary Dietz,David Balli,William J. Geese,Chunzhe Duan,Yu-Han Hung,Virginia Ip,Gerald Li,Ryon P. Graf,Neal Ready
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:31 (24): 5198-5210 被引量:3
标识
DOI:10.1158/1078-0432.ccr-25-0952
摘要

PURPOSE: Low-density lipoprotein receptor-related protein 1b (LRP1b) is a cell surface receptor, commonly altered in many cancers and associated with improved responses, progression-free survival (PFS), and overall survival with immune checkpoint inhibition. EXPERIMENTAL DESIGN: LRP1b alterations were determined by whole-exome sequencing and associated with PFS and objective response rates in patients with non-small cell lung cancer (NSCLC) in a post hoc analysis of the randomized controlled phase III CheckMate-026 (CM026) trial (NCT02041533) examining chemotherapy compared with nivolumab, adjusting for tumor mutational burden (TMB) and clinical features. We separately evaluated a deidentified nationwide (US-based) NSCLC clinico-genomic database for associations of LRP1b alterations and PFS with anti-PD-1 immunotherapy. RESULTS: In the clinico-genomic database cohort of patients with NSCLC (N = 18,369), LRP1b mutations were positively associated with TP53/KRAS alterations and inversely with EGFR/RET/MET/ERBB2 alterations and significantly improved PFS with PD-1 inhibition (n = 1,569; adjusted HR, 0.86; P = 0.014). In CheckMate-026, patients with LRP1b alterations had a statistically significant improvement in objective response rate to nivolumab versus LRP1b wild-type patients (OR 3.5; 95% confidence interval, 1.71-7.13; P = 0.0006) but not with chemotherapy (OR 0.63; 95% confidence interval, 0.32-1.26; P = 0.19), adjusting for TMB, age, gender, histology, smoking, and performance status. LRP1b mutations were associated with improved PFS with nivolumab (HR, 0.66; P = 0.04) but not chemotherapy (HR, 1.26; P = 0.25), also maintained in multivariate and TMB-adjusted analyses. CONCLUSIONS: LRP1b mutations are a candidate predictive biomarker for immune checkpoint inhibition versus chemotherapy in NSCLC. Further mechanistic characterization of LRP1b and prospective validation are warranted and might enable future clinical use.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
纳古菌完成签到,获得积分10
1秒前
SG完成签到,获得积分10
1秒前
听话的无极完成签到,获得积分10
1秒前
1秒前
123456完成签到,获得积分10
2秒前
努力小人完成签到,获得积分10
2秒前
3秒前
liang完成签到,获得积分10
3秒前
3秒前
青葙完成签到,获得积分10
4秒前
123456发布了新的文献求助10
5秒前
11NING发布了新的文献求助10
6秒前
Ysk完成签到,获得积分10
6秒前
8秒前
675675发布了新的文献求助10
10秒前
汉堡包的应助被小艾同学采纳,获得10
10秒前
11秒前
14秒前
11NING完成签到,获得积分10
14秒前
14秒前
SCI完成签到,获得积分10
15秒前
Koi发布了新的文献求助10
15秒前
禹hs完成签到,获得积分10
18秒前
吱ing完成签到 ,获得积分10
19秒前
ding的应助被bbb采纳,获得10
19秒前
SCI发布了新的文献求助10
19秒前
ZeSheng完成签到,获得积分10
20秒前
21秒前
21秒前
21秒前
眠龙完成签到 ,获得积分10
22秒前
猪猪侠完成签到,获得积分10
23秒前
23秒前
23秒前
英俊的铭的应助被xxx采纳,获得10
24秒前
水煮电吹风的应助被叶95采纳,获得10
24秒前
ylfs完成签到,获得积分10
24秒前
25秒前
bobo完成签到,获得积分10
26秒前
小艾同学发布了新的文献求助10
26秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181658
求助须知:如何正确求助?哪些是违规求助? 9571454
关于积分的说明 21818081
捐赠科研通 7777987
什么是DOI,文献DOI怎么找? 3433508
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479568